✦ LIBER ✦

De novo Therapy with Everolimus, Low-Dose Ciclosporine A, Basiliximab and Steroid Elimination in Pediatric Kidney Transplantation

✍ Scribed by L. Pape; G. Offner; M. Kreuzer; K. Froede; J. Drube; N. Kanzelmeyer; J. H. H. Ehrich; T. Ahlenstiel

Book ID: 114805728
Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 187 KB
Volume: 10
Category: Article
ISSN: 1600-6135
DOI: 10.1111/j.1600-6143.2010.03266.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

De novo therapy with everolimus and redu

De novo therapy with everolimus and reduced-exposure cyclosporine following pediatric kidney transplantation: A prospective, multicenter, 12-month study

✍ Grushkin, Carl; Mahan, John D.; Mange, Kevin C.; Hexham, J.Mark; Ettenger, Rober 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 142 KB

Comparison of outcomes with low-dose ant

Comparison of outcomes with low-dose anti-thymocyte globulin, basiliximab or no induction therapy in pediatric kidney transplant recipients: A retrospective study

✍ Pedro W. Baron; Okechukwu N. Ojogho; Peter Yorgin; Shobha Sahney; Drew Cutler; R 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 165 KB

Efficacy and safety of de novo or early

Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial

✍ Jacques Dantal; François Berthoux; Marie-Christine Moal; Lionel Rostaing; Christ 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 335 KB

High-dose therapy and autologous periphe

High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients

✍ Massimo Martino; Giuseppe Console; Giuseppe Irrera; Giulia Praticò; Caterina Ste 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 240 KB 👁 2 views

## Abstract The recent development of reduced intensity conditioning and allotransplantation (RICT) has opened a new way to assure engraftment of donor cells while reducing early transplant‐related mortality. We evaluated the combination of high‐dose therapy and autologous peripheral blood stem cel